Mindy Kim Graham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mindy Kim Graham has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Christopher M. Heaphy
Department of Medicine, Section of Hematology-Medical Oncology, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, MA
50 shared publications - Srinivasan Yegnasubramanian
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
41 shared publications - Alan K. Meeker
Johns Hopkins University School of Medicine, Baltimore, MD
39 shared publications - Beisi Xu
Center for Applied Bioinformatics, St. Jude Childrenās Research Hospital, Memphis, TN 38105, USA
32 shared publications - Michael A. Dyer
St. Jude Children's Research Hospital
32 shared publications - Christine Davis
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
31 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published byĀ WileyĀ inĀ The Journal of Pathology
- Vol.Ā 270 Ā (4) , 481-496
A transition zone enriched WIF1 + basal cell subtype is associated with benign prostatic hyperplasia
The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the transition zone (TZ). Through extensive singleācell RNA sequencing (scRNAāseq) of benign regions from prostatectomy specimens, we identified a basal cell population expressing WIF1 , VCAN , and NRG1 , among other genes, that was significantly enriched in the TZ. Analysis of previously published scRNAāseq datasets further confirmed that WIF1 + basal cells were significantly enriched in BPH compared with normal prostate. Pathway and cellācell communication analyses revealed that this basal subtype is associated with programs related to cell proliferation, epithelialāmesenchymal transition, immune regulation, angiogenesis, and hormone response. Together, the molecular signature, zonal distribution, and pathway enrichment suggest that TZāenriched WIF1 + basal cells may contribute to BPH pathogenesis by promoting epithelial and stromal remodeling. Ā© 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 10 September 2026
- Published byĀ WileyĀ inĀ The Journal of Pathology
- Vol.Ā 270 Ā (4) , 481-496
Open AccessA transition zone enriched WIF1 + basal cell subtype is associated with benign prostatic hyperplasia
The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the transition zone (TZ). Through extensive singleācell RNA sequencing (scRNAāseq) of benign regions from prostatectomy specimens, we identified a basal cell population expressing WIF1 , VCAN , and NRG1 , among other genes, that was significantly enriched in the TZ. Analysis of previously published scRNAāseq datasets further confirmed that WIF1 + basal cells were significantly enriched in BPH compared with normal prostate. Pathway and cellācell communication analyses revealed that this basal subtype is associated with programs related to cell proliferation, epithelialāmesenchymal transition, immune regulation, angiogenesis, and hormone response. Together, the molecular signature, zonal distribution, and pathway enrichment suggest that TZāenriched WIF1 + basal cells may contribute to BPH pathogenesis by promoting epithelial and stromal remodeling. Ā© 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
A transition zone enriched WIF1āŗ basal cell subtype is associated with benign prostatic hyperplasia
The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Through extensive single-cell RNA sequencing (scRNA-seq) of benign regions from prostatectomy specimens, we identified a basal cell population expressing WIF1, VCAN, and NRG1, among other genes, that was significantly enriched in the transition zone (TZ). Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the TZ. Analysis of previously published scRNA-seq datasets further confirmed that WIF1āŗ basal cells were significantly enriched in BPH compared to normal prostate. Pathway and cell-cell communication analyses revealed that this basal subtype is associated with programs related to cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, and hormone response. Together, the molecular signature, zonal distribution, and pathway enrichment suggest that TZ-enriched WIF1āŗ basal cells may contribute to BPH pathogenesis by promoting epithelial and stromal remodeling.
Open AccessA transition zone enriched WIF1āŗ basal cell subtype is associated with benign prostatic hyperplasia
The cellular composition and disease susceptibilities of the distinct zones of the human prostate remain incompletely understood. Through extensive single-cell RNA sequencing (scRNA-seq) of benign regions from prostatectomy specimens, we identified a basal cell population expressing WIF1, VCAN, and NRG1, among other genes, that was significantly enriched in the transition zone (TZ). Benign prostatic hyperplasia (BPH) is a common condition that causes widespread morbidity and is nearly exclusively localized to the TZ. Analysis of previously published scRNA-seq datasets further confirmed that WIF1āŗ basal cells were significantly enriched in BPH compared to normal prostate. Pathway and cell-cell communication analyses revealed that this basal subtype is associated with programs related to cell proliferation, epithelial-mesenchymal transition (EMT), angiogenesis, and hormone response. Together, the molecular signature, zonal distribution, and pathway enrichment suggest that TZ-enriched WIF1āŗ basal cells may contribute to BPH pathogenesis by promoting epithelial and stromal remodeling.
- Open Access
Loss of DAXX induces alternative lengthening of telomeres (ALT)-associated hallmarks in prostate cancer cells in a context-specific manner
Background: The histone chaperone complex, consisting of the death domaināassociated protein (DAXX) and the alpha-thalassemia/mental retardation X-linked protein (ATRX), plays a pivotal role in maintaining chromatin through the deposition of the histone variant H3.3. Mutations leading to loss of ATRX or DAXX function are linked to the non-telomerase, alternative lengthening of telomeres (ALT) phenotype in certain cancers. Engineered ATRX mutations have previously been found to induce features of ALT in prostate cancer cell lines, notably in LAPC-4, but not in CWR22Rv1. This study determined the impact of DAXX mutations on ALT-associated characteristics in CWR22Rv1 and LAPC-4. Methodology: Mutations were induced in CWR22Rv1 and LAPC-4 cells by targeting exon 2 of DAXX using the CRISPR-Cas9 genome editing strategy. The resulting mutant clones were then evaluated for ALT-associated characteristics, including the presence of ALT-associated PML bodies (APBs), C-circles, telomere length heterogeneity, and a lack of telomerase activity. Results: Four CWR22Rv1 DAXX mutant clones ( DAXX Mut 1 - 4 ) and five LAPC-4 clones ( DAXX Mut 1-5 ) were evaluated. In CWR22Rv1, DAXX Mut 1, DAXX Mut 2, and DAXX Mut 4 were true knockout clones with frameshift mutations in both copies, while CWR22Rv1 DAXX Mut 3 had a frameshift mutation in one copy and an in-frame mutation in the other. Protein expression was undetectable in all the CWR22Rv1 clones, including CWR22Rv1 DAXX Mut 3 . In LAPC-4, DAXX Mut 1 was a true knockout, while DAXX Mut 2, DAXX Mut 3, DAXX Mut 4 , and DAXX Mut 5 clones had at least one in-frame mutation. Among these LAPC-4 clones, only DAXX Mut 1 had undetectable protein by western blotting. ALT-associated characteristics such as APBs, C-circles, and telomere length heterogeneity were observed only in CWR22Rv1 DAXX Mut 4 . All the clones maintained telomerase activity, regardless of whether ALT-associated hallmarks were observed. Implications: The CWR22Rv1 and LAPC-4 DAXX mutant clone models provide useful tools for future studies on telomere maintenance mechanisms and DAXX-related biology, particularly in prostate cancer.
Open AccessLoss of DAXX induces alternative lengthening of telomeres (ALT)-associated hallmarks in prostate cancer cells in a context-specific manner
Background: The histone chaperone complex, consisting of the death domaināassociated protein (DAXX) and the alpha-thalassemia/mental retardation X-linked protein (ATRX), plays a pivotal role in maintaining chromatin through the deposition of the histone variant H3.3. Mutations leading to loss of ATRX or DAXX function are linked to the non-telomerase, alternative lengthening of telomeres (ALT) phenotype in certain cancers. Engineered ATRX mutations have previously been found to induce features of ALT in prostate cancer cell lines, notably in LAPC-4, but not in CWR22Rv1. This study determined the impact of DAXX mutations on ALT-associated characteristics in CWR22Rv1 and LAPC-4. Methodology: Mutations were induced in CWR22Rv1 and LAPC-4 cells by targeting exon 2 of DAXX using the CRISPR-Cas9 genome editing strategy. The resulting mutant clones were then evaluated for ALT-associated characteristics, including the presence of ALT-associated PML bodies (APBs), C-circles, telomere length heterogeneity, and a lack of telomerase activity. Results: Four CWR22Rv1 DAXX mutant clones ( DAXX Mut 1 - 4 ) and five LAPC-4 clones ( DAXX Mut 1-5 ) were evaluated. In CWR22Rv1, DAXX Mut 1, DAXX Mut 2, and DAXX Mut 4 were true knockout clones with frameshift mutations in both copies, while CWR22Rv1 DAXX Mut 3 had a frameshift mutation in one copy and an in-frame mutation in the other. Protein expression was undetectable in all the CWR22Rv1 clones, including CWR22Rv1 DAXX Mut 3 . In LAPC-4, DAXX Mut 1 was a true knockout, while DAXX Mut 2, DAXX Mut 3, DAXX Mut 4 , and DAXX Mut 5 clones had at least one in-frame mutation. Among these LAPC-4 clones, only DAXX Mut 1 had undetectable protein by western blotting. ALT-associated characteristics such as APBs, C-circles, and telomere length heterogeneity were observed only in CWR22Rv1 DAXX Mut 4 . All the clones maintained telomerase activity, regardless of whether ALT-associated hallmarks were observed. Implications: The CWR22Rv1 and LAPC-4 DAXX mutant clone models provide useful tools for future studies on telomere maintenance mechanisms and DAXX-related biology, particularly in prostate cancer.
- Open Access
Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer
Aberrant microRNA expression is common in cancer, yet cell-type-specific microRNA activity in the tumor microenvironment (TME) remains poorly understood. Here, we show that germline deletion of miR-21 significantly attenuated the progression of MYC-driven prostate cancer (PCa), reducing prostate weight, tumor burden, and proliferation index in Hi-Myc mice. In situ hybridization revealed elevated miR-21 expression in multiple cell types during disease progression. Inflammatory and premalignant lesions in mouse and human prostate showed increased miR-21 in both stroma and epithelium, with further enrichment in the stroma of invasive adenocarcinoma. In Hi-Myc mice, single cell RNA-sequencing revealed miR-21 gene regulation in neoplastic, stromal, and immune cells in a cell-type-specific manner, impacting both direct and indirect targets. Notably, miR-21 deletion reduced immune infiltration into the prostate TME, particularly Trem2 -expressing macrophages and regulatory T cells. The Timp1-fibroblast gene signature in MYC-driven PCa was suppressed in miR-21 knockout prostates. Cell-cell communication analysis showed that miR-21 suppressed TGF-beta signaling in the TME, partially through Ski and Smad7 suppression in cancer-associated fibroblasts. These findings underscore the crucial role of miR-21 in PCa and provide some of the first in situ insights into cell-type-specific miRNA activity in solid tumors.
Open AccessCell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer
Aberrant microRNA expression is common in cancer, yet cell-type-specific microRNA activity in the tumor microenvironment (TME) remains poorly understood. Here, we show that germline deletion of miR-21 significantly attenuated the progression of MYC-driven prostate cancer (PCa), reducing prostate weight, tumor burden, and proliferation index in Hi-Myc mice. In situ hybridization revealed elevated miR-21 expression in multiple cell types during disease progression. Inflammatory and premalignant lesions in mouse and human prostate showed increased miR-21 in both stroma and epithelium, with further enrichment in the stroma of invasive adenocarcinoma. In Hi-Myc mice, single cell RNA-sequencing revealed miR-21 gene regulation in neoplastic, stromal, and immune cells in a cell-type-specific manner, impacting both direct and indirect targets. Notably, miR-21 deletion reduced immune infiltration into the prostate TME, particularly Trem2 -expressing macrophages and regulatory T cells. The Timp1-fibroblast gene signature in MYC-driven PCa was suppressed in miR-21 knockout prostates. Cell-cell communication analysis showed that miR-21 suppressed TGF-beta signaling in the TME, partially through Ski and Smad7 suppression in cancer-associated fibroblasts. These findings underscore the crucial role of miR-21 in PCa and provide some of the first in situ insights into cell-type-specific miRNA activity in solid tumors.
- Open Access
- 28 August 2024
- Published byĀ Springer NatureĀ inĀ Nature Communications
- Vol.Ā 15 Ā (1) , 1-20
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer
How prostate cancer cells and their precursors mediate changes in the tumor microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the inability to longitudinally study the disease evolution in human tissues. To overcome this limitation, we perform extensive single-cell RNA-sequencing (scRNA-seq) and molecular pathology of the comparative biology between human prostate cancer and key stages in the disease evolution of a genetically engineered mouse model (GEMM) of prostate cancer. Our studies of human tissues reveal that cancer cell-intrinsic activation of MYC signaling is a common denominator across the well-known molecular and pathological heterogeneity of human prostate cancer. Cell communication network and pathway analyses in GEMMs show that MYC oncogene-expressing neoplastic cells, directly and indirectly, reprogram the TME during carcinogenesis, leading to a convergence of cell state alterations in neighboring epithelial, immune, and fibroblast cell types that parallel key findings in human prostate cancer.
- 28 August 2024
- Published byĀ Springer NatureĀ inĀ Nature Communications
- Vol.Ā 15 Ā (1) , 1-20
Open AccessConvergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer
How prostate cancer cells and their precursors mediate changes in the tumor microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the inability to longitudinally study the disease evolution in human tissues. To overcome this limitation, we perform extensive single-cell RNA-sequencing (scRNA-seq) and molecular pathology of the comparative biology between human prostate cancer and key stages in the disease evolution of a genetically engineered mouse model (GEMM) of prostate cancer. Our studies of human tissues reveal that cancer cell-intrinsic activation of MYC signaling is a common denominator across the well-known molecular and pathological heterogeneity of human prostate cancer. Cell communication network and pathway analyses in GEMMs show that MYC oncogene-expressing neoplastic cells, directly and indirectly, reprogram the TME during carcinogenesis, leading to a convergence of cell state alterations in neighboring epithelial, immune, and fibroblast cell types that parallel key findings in human prostate cancer.
- Open Access
- 20 June 2024
- Published byĀ American Association for Cancer Research (AACR)
FIGURE 4 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
TERT is a bona fide MYCN target. A, Alignments of DNA methylation from WGBS and MYCN-ChIP-seq in three MYCN-amplified neuroblastoma O-PDX models and cell line (SKNBE2) showing that MYCN binding overlaps with the hypomethylated region in the TERT promoter. The core promoter is shaded in red and THOR is shaded in yellow. B, Western blot analysis for MYCN and GAPDH (loading control) in different indicated doxycycline-inducible engineered cell lines to ectopically express MYCN in nonāMYCN-amplified cells (left) or to express three different MYCN-shRNAs (indicated as A, B, C) in MYCN-amplified neuroblastoma cells (right). Relative MYCN band intensities in cells expressing MYCN-shRNA are indicated on top of the blots. C, A schematic representation of Luciferase reporter construct. The long construct contains the luciferase gene, and the TERT promoter core and THOR sequences, while the short construct does not contain the THOR promoter sequence. D, Fold change of Luciferase luminescence for the short construct (top) and the long construct (bottom) compared with control vehicle-treated controls. E, Fold change of TERT expression in the same cells measured by qRT-PCR. *, P < 0.05, error bars represent SD.
- 20 June 2024
- Published byĀ American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
TERT is a bona fide MYCN target. A, Alignments of DNA methylation from WGBS and MYCN-ChIP-seq in three MYCN-amplified neuroblastoma O-PDX models and cell line (SKNBE2) showing that MYCN binding overlaps with the hypomethylated region in the TERT promoter. The core promoter is shaded in red and THOR is shaded in yellow. B, Western blot analysis for MYCN and GAPDH (loading control) in different indicated doxycycline-inducible engineered cell lines to ectopically express MYCN in nonāMYCN-amplified cells (left) or to express three different MYCN-shRNAs (indicated as A, B, C) in MYCN-amplified neuroblastoma cells (right). Relative MYCN band intensities in cells expressing MYCN-shRNA are indicated on top of the blots. C, A schematic representation of Luciferase reporter construct. The long construct contains the luciferase gene, and the TERT promoter core and THOR sequences, while the short construct does not contain the THOR promoter sequence. D, Fold change of Luciferase luminescence for the short construct (top) and the long construct (bottom) compared with control vehicle-treated controls. E, Fold change of TERT expression in the same cells measured by qRT-PCR. *, P < 0.05, error bars represent SD.
- Open Access
- 20 June 2024
- Published byĀ American Association for Cancer Research (AACR)
FIGURE 2 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
Molecular characterization of telomere maintenance in neuroblastoma cell lines. Telomere maintenance mechanism was assessed in eight neuroblastoma cell lines used in this study: MYCN-amplified (NB5, SKNBE2, IMR32), moderate level of MYCN without amplification (NBL-S), ATRX-mutant (SKNMM, CHLA90), low-DAXX (SKNFI) and ever-shorter telomere (LAN6) neuroblastoma cells. A, Representative images of Telomere FISH (green) showing brighter signal in cell lines with long telomeres. B, Telomeric repeats in neuroblastoma cell lines relative to those in the telomerase-positive 293T cells using qPCR. Telomerase-negative, ALT-positive U2OS cells were used as a positive control for long telomeres. C, Representative blot of C-circle assay. U2OS cells were used as a positive control and PC3 cells were used as a negative control. The amount of DNA in nanograms (ng) is indicated on the blot. All reactions were done in the presence or absence of the Phi 29 (Phi) DNA polymerase. qRT-PCR was performed in neuroblastoma cell lines to measure TERT (D) and TERC (E) expression relative to the telomerase-positive 293T cell line. Gene expression was normalized to HPRT expression. The U2OS cell line was used as an ALT-positive control and does not express TERC.
- 20 June 2024
- Published byĀ American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres
Molecular characterization of telomere maintenance in neuroblastoma cell lines. Telomere maintenance mechanism was assessed in eight neuroblastoma cell lines used in this study: MYCN-amplified (NB5, SKNBE2, IMR32), moderate level of MYCN without amplification (NBL-S), ATRX-mutant (SKNMM, CHLA90), low-DAXX (SKNFI) and ever-shorter telomere (LAN6) neuroblastoma cells. A, Representative images of Telomere FISH (green) showing brighter signal in cell lines with long telomeres. B, Telomeric repeats in neuroblastoma cell lines relative to those in the telomerase-positive 293T cells using qPCR. Telomerase-negative, ALT-positive U2OS cells were used as a positive control for long telomeres. C, Representative blot of C-circle assay. U2OS cells were used as a positive control and PC3 cells were used as a negative control. The amount of DNA in nanograms (ng) is indicated on the blot. All reactions were done in the presence or absence of the Phi 29 (Phi) DNA polymerase. qRT-PCR was performed in neuroblastoma cell lines to measure TERT (D) and TERC (E) expression relative to the telomerase-positive 293T cell line. Gene expression was normalized to HPRT expression. The U2OS cell line was used as an ALT-positive control and does not express TERC.